Joanne Wuensch
Stock Analyst at Citigroup
(4.52)
# 294
Out of 4,667 analysts
362
Total ratings
68.5%
Success rate
13.13%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IART Integra LifeSciences Holdings | Maintains: Sell | $16 → $22 | $22.99 | -4.31% | 14 | Nov 5, 2024 | |
| BLCO Bausch + Lomb | Maintains: Buy | $20 → $24 | $19.62 | +22.32% | 3 | Oct 31, 2024 | |
| SYK Stryker | Maintains: Buy | $406 → $411 | $387.96 | +5.94% | 11 | Oct 31, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $92 → $98 | $91.34 | +7.29% | 32 | Oct 24, 2024 | |
| JNJ Johnson & Johnson | Maintains: Buy | $180 → $185 | $154.31 | +19.89% | 11 | Oct 16, 2024 | |
| NVRO Nevro | Maintains: Neutral | $6.89 → $6 | $4.36 | +37.61% | 18 | Oct 1, 2024 | |
| MDT Medtronic | Maintains: Neutral | $85 → $92 | $84.64 | +8.70% | 18 | Oct 1, 2024 | |
| ITGR Integer Holdings | Maintains: Neutral | $124 → $130 | $135.66 | -4.17% | 3 | Oct 1, 2024 | |
| PODD Insulet | Maintains: Buy | $250 → $275 | $264.26 | +4.06% | 12 | Oct 1, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Neutral | $45 → $50 | $43.00 | +16.28% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $77 | $70.02 | +9.97% | 18 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $40 | $32.94 | +21.43% | 19 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $178 → $200 | $237.87 | -15.92% | 23 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $74.06 | +48.53% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $512 → $560 | $546.78 | +2.42% | 14 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $86.45 | -1.67% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $108.88 | +10.21% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $6.5 | $3.78 | +71.96% | 8 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $132 | $143.28 | -7.87% | 19 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 → $57 | $31.83 | +79.08% | 12 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $103 | $83.20 | +23.80% | 2 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $161 | $74.94 | +114.85% | 11 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $116 | $99.68 | +16.38% | 18 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $128 | $115.92 | +10.42% | 19 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $6.28 | +170.70% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $224.04 | +11.59% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $85.84 | -19.61% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $241.87 | -47.49% | 6 | Dec 10, 2018 |
Integra LifeSciences Holdings
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $22.99
Upside: -4.31%
Bausch + Lomb
Oct 31, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $19.62
Upside: +22.32%
Stryker
Oct 31, 2024
Maintains: Buy
Price Target: $406 → $411
Current: $387.96
Upside: +5.94%
Boston Scientific
Oct 24, 2024
Maintains: Buy
Price Target: $92 → $98
Current: $91.34
Upside: +7.29%
Johnson & Johnson
Oct 16, 2024
Maintains: Buy
Price Target: $180 → $185
Current: $154.31
Upside: +19.89%
Nevro
Oct 1, 2024
Maintains: Neutral
Price Target: $6.89 → $6
Current: $4.36
Upside: +37.61%
Medtronic
Oct 1, 2024
Maintains: Neutral
Price Target: $85 → $92
Current: $84.64
Upside: +8.70%
Integer Holdings
Oct 1, 2024
Maintains: Neutral
Price Target: $124 → $130
Current: $135.66
Upside: -4.17%
Insulet
Oct 1, 2024
Maintains: Buy
Price Target: $250 → $275
Current: $264.26
Upside: +4.06%
Establishment Labs Holdings
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $43.00
Upside: +16.28%
Oct 1, 2024
Maintains: Buy
Price Target: $83 → $77
Current: $70.02
Upside: +9.97%
Oct 1, 2024
Maintains: Neutral
Price Target: $38 → $40
Current: $32.94
Upside: +21.43%
Aug 22, 2024
Maintains: Neutral
Price Target: $178 → $200
Current: $237.87
Upside: -15.92%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $74.06
Upside: +48.53%
Aug 22, 2024
Maintains: Buy
Price Target: $512 → $560
Current: $546.78
Upside: +2.42%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $86.45
Upside: -1.67%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $108.88
Upside: +10.21%
Jul 10, 2024
Maintains: Neutral
Price Target: $6 → $6.5
Current: $3.78
Upside: +71.96%
Jul 10, 2024
Downgrades: Neutral
Price Target: $130 → $132
Current: $143.28
Upside: -7.87%
May 22, 2024
Upgrades: Buy
Price Target: $40 → $57
Current: $31.83
Upside: +79.08%
Apr 3, 2024
Maintains: Buy
Price Target: $88 → $103
Current: $83.20
Upside: +23.80%
Apr 3, 2024
Maintains: Buy
Price Target: $148 → $161
Current: $74.94
Upside: +114.85%
Apr 3, 2024
Maintains: Buy
Price Target: $108 → $116
Current: $99.68
Upside: +16.38%
Apr 3, 2024
Maintains: Buy
Price Target: $126 → $128
Current: $115.92
Upside: +10.42%
Feb 23, 2024
Maintains: Buy
Price Target: $16 → $17
Current: $6.28
Upside: +170.70%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $224.04
Upside: +11.59%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $85.84
Upside: -19.61%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $241.87
Upside: -47.49%